Study wrapper · #894
Incident Diabetic Retinopathy after Adjunctive Tirzepatide Treatment for 1 Year in Adults with Type 1 Diabetes.
Polsky S, Beck E, Shah A, et al. Diabetes technology & therapeutics. 2026.
DOI: 10.1177/15209156261468108PubMed: 42452840
Editor's note
This small retrospective cohort examined diabetic retinopathy incidence after a year of off-label tirzepatide in overweight type 1 diabetes patients. New retinopathy occurred at rates comparable to controls, with rapid HbA1c decline the more consistent risk factor. Tirzepatide is a genuine subject, but the sample is small and randomized trials are needed to confirm the safety signal.
Plain-language abstract
In a retrospective chart review of overweight adults with type 1 diabetes, one year of off-label tirzepatide was associated with rates of new diabetic retinopathy similar to untreated controls.
Related coverage
Weak / none
Cost-effectiveness of tirzepatide versus semaglutide for patients with obesity or overweight in the US: evidence from the SURMOUNT-5 head-to-head phase-3 trial.
Journal of medical economicsn=——2026
Mixed
Sleeve gastrectomy versus tirzepatide to improve survival among patients with stage 5 CKD: A Markov decision analysis.
American journal of surgeryn=——2026
Mixed
Development and validation of a multiplexed LC-HRMS method for nine GLP-1 receptor agonists and its pharmaceutical application.
Journal of chromatography. An=——2026